Analysis of correlation between weight at diagnosis, weight gain after breast cancer treatment, and recurrence in women with early-stage breast cancer (EBC).

Abstract

e11001 Background: Overweight at the time of EBC diagnosis has been linked frequently to poorer survival in most studies and some evidence suggests that women who gain weight after breast cancer diagnosis are at increased risk of cancer recurrence and death. Most previous studies on this topic have relied on retrospective chart reviews. The aim of this prospective, observational, single-center study is to determine whether weight at diagnosis and weight gain after EBC treatment can be predictive of BC recurrence. Methods: From December 1990 to January 2012, the study included atotal of 311 EBC patients (stage I-IIIa).We assessed weight and body mass index (BMI=kg/m2) at baseline (≤ 1 month after surgery) and 24 months after completion of treatment (chemotherapy ± radiotherapy). The chi square test (X2) was conducted to determine if a significant correlation exists between BC recurrence and 3 categories of BMI at diagnosis (lean weight: BMI <25; overweight: BMI 25-30; obese: BMI >25) and BC recurrence and weight changes after EBC treatment (loss of <1 kg/m2; loss of ≥ 1 kg/m2; gain of <2kg/m2; gain of >2 kg/m2). Results: Median age was 56 years (range28-81); 68% of patients were postmenopausal, stage I-II in 88%; ER+/PGR+ in 66%; ER+/PGR- in 12%; HER2+ in 14%; 72% underwent conservative surgery+radiotherapy; 57% received chemotherapy (CT) and 78% received endocrine therapy alone or after CT. Median BMI at diagnosis was 27.03, after treatment 28.04. After a median follow-up of 13 years 104 patients recurred. Statistical analysis is reported in the table. Conclusions: Our findings show that EBC patients gain weight after treatment. No significant correlation was found between weight at diagnosis, weight changes after EBC treatment and recurrence. At ASCO meeting we will report results of the prognostic associations of baseline biological features, menopausal status and comorbid disease. [Table: see text]